FETOPLACENTAL INSUFFICIENCY AS A REASON OF OFFSPRING OXIDATIVE STATUS DISTURBANCES

Authors

  • Seliukova N. Yu. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine; 2 National University of Pharmacy, Kharkiv, Ukraine
  • Misiura K. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Boiko M. O. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Kustova S. P. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Grushanska N. H. National University of Life and Environmental Sciences of Ukraine, Kiev, Ukraine
  • Sharandak P. V. Ministry for Development of Economy, Trade and Agriculture of Ukraine, Kiev, Ukraine
  • Medvedovska N. V. Scientific and coordination department NAMS of Ukraine, Kiev, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2020.2.15

Keywords:

fetoplacental insufficiency, offspring, oxidative status, therapy

Abstract

The aim of this scientific work was to determine the influence of the experimental fetoplacental insufficiency on the both sex offspring oxidative status during puberty and to estimate the efficiency of base and complex
therapy during pregnancy.
Materials. The healthy, Vistar mature rat’s females of young (3–4 months) and mature (8–10 months)
reproductive age have been used for both sex offspring obtaining. 8 groups for 7 pregnant females in each
have been formed: Groups I and II — intact animals of young and mature reproductive age; Group III and
IV — females with experimental Fetoplacental insufficiency (FPI) of young and mature reproductive age accordingly; Groups V and VI — young and mature animals with experimental FPI treated by pharmaceutical
composition which contains nontoxic active pharmaceutical ingredients of FPI basic therapeutic group — amino
acid (L-arginine), dicarbonic acid (succinic acid), vitamins (folic acid) and vasoactive drug (dipyridamole).
Experimental animals have received treatment from 11 to 19 day of pregnancy. Groups VII and VIII — young
and mature animals with experimental FPI treated by drug of comparison — dipyridamole. The modeling of
FPI has been carried out by daily subcutaneous introduction of 50 % tetrachlormethane oil solution in dose of
2 ml/kg of body weight from 12 to 18 day of pregnancy. Animals — offspring have been killed on the 50th day of
life (puberty period) by quick decapitation without general anesthesia to avoid negative effects on sex hormones
level and antioxidant enzymes systems.
Results. The effect of experimental fetoplacental insufficiency in rats of young and mature reproductive
age on the oxidative status formation in offspring of both sexes during puberty was determined and the effects
of basic and complex therapy during pregnancy were evaluated. It was revealed that fetoplacental insufficiency
in the second half of pregnancy leads to the formation in offspring of both sexes, but more pronounced in male
offspring, during the puberty, an altered pattern of the antioxidant system enzymatic activity, which is realized
in increased levels of both primary and final products of lipoperoxidation and may be the basis for further development of chronic diseases. More pronounced disorders were observed in the offspring of mothers of mature
reproductive age, which may be due to the additional influence of involutive processes in the placenta. The use
of a vasodilator drug alone and, more effectively in combination, significantly restored the studied parameters

References

Reznikov AG, Pishak VP, Nosenko ND, et al. Prenatal’nyj stress i nejrojendokrinnaja patologija, Chernovcy, 2004: 318 p.

Petraglia F, Imperatore A, Challis JRG. Endocrine Rev 2010; 31(6): 783-816. doi: http://doi.org/10.1210/er.2009-0019

Chepka JL. Ukr Med Chasopys 2001; 6: 108-115.

Lihachov VK, Petrenko JV. Problemy, dostizhenija i perspektivy razvitija mediko-biologicheskih nauk i prakticheskogo zdravoohranenija: Tr. KGMU.ym. S. Y. Georgyevskogo, Symferopol 2009; 145(3): 151-155.

Shherbakov AJ, Tihaja IA, Shherbakov VJ, Novikova EA. Mezhdunar Med Zhurn 2012; 3: 50-53.

Baker DJ. Clin Sci 1998; 95: 115-128.

Cheedipudi S, Genolet O, Dobreva G. Front Genet 2014; 5: 19. doi: http://doi.org/10.3389/ fgene.2014.00019

Zhu Z, Cao F, Li X. Front Endocrinol 2019; 10: 764. doi: http://doi.org/10.3389/fendo.2019.00764

Sahin E, DePinho RA. Nat Rev Mol Cell Biol 2012; 13(6): 397-404. doi: http://doi.org/10.1038/nrm3352

Menezo YJ, Silvestris E, Dale B, Elder K. Reprod Biomed Online 2016; 33(6): 668-683. doi: http://doi.org/10.1016/j.rbmo. 2016.09.006

Dimova LG, Battista S, Plosch T, et al. Redox Biol 2020; 28: 101329. doi: http://doi.org/ 10.1016/j.redox.2019.101329

Badran M, Yassin BA, Lin DTS, et al. J Physiol 2019; 597(22): 5349-5364. doi: http://doi.org/10.1113/JP277936

Reznikov OG. Endokrynologija 2003; 8(1): 142-145.

Jakovljeva LV, Zajchenko GV, Cypkun AG, et al. Doklinichne vyvchennja likars’kyh zasobiv, pryznachenyh dlja likuvannja placentarnoi’ dysfunkcii’: metod. Rekomendacii’, Kyi’v, 2009.

Placer Z, Vidlakova M, Kupila L. Chehosl Med Obzor 1970; 16(1): 30-34.

Stal’naja ID, Garishvili GT. Sovremennye metody biohimii, Moskva, 1977: 43-44.

Koroljuk A, Ivanova L, Majorova I, Tokarev VE. Lab Delo 1988; 1: 16-17.

Chevari S, Andjal T, Shtrenger J. Lab Delo 1991; 10: 9-13.

Lankin VZ, Tihadze AN, Kovalevskaja AL, et al. Doklady AN SSSR 1981; 261(3): 18-24.

Beutler E, Duron O, Kelly B. Lab Сlin Med 1963; 63(5): 882-888

Downloads

Published

2021-06-30

How to Cite

Seliukova, N. Y. . ., Misiura, K. V. ., Boiko, M. O. ., Kustova, S. P. ., Grushanska, N. H. ., Sharandak, . P. V., & Medvedovska, N. V. (2021). FETOPLACENTAL INSUFFICIENCY AS A REASON OF OFFSPRING OXIDATIVE STATUS DISTURBANCES. Problems of Endocrine Pathology, 72(2), 121-127. https://doi.org/10.21856/j-PEP.2020.2.15

Most read articles by the same author(s)

1 2 > >>